Evidence map›Paper›PMID 26350581›Full record

ArticleAngewandte Chemie (International ed. in English)2015

Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines.

Giuseppe Stefanetti, Qi-Ying Hu, Aimee Usera, Zack Robinson, Martin Allan, Alok Singh, Hidetomo Imase, Jennifer Cobb, Huili Zhai, Douglas Quinn and 5 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Optimization Strategies and Synergistic Applications of EngineeredInternational journal of nanomedicine · 2026
    Review
  2. Article
  3. Review
  4. Site-Specific Multi-Functionalization of the Carrier Protein CRMChembiochem : a European journal of chemical biology · 2022
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Rational Design of a Glycoconjugate Vaccine against Group AInternational journal of molecular sciences · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. AnomericMolecules (Basel, Switzerland) · 2018
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giuseppe StefanettiSclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy).
Qi-Ying HuNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA). qiying.hu@novartis.com.
Aimee UseraNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Zack RobinsonNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Martin AllanNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Alok SinghNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Hidetomo ImaseNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Jennifer CobbNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Huili ZhaiNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Douglas QuinnNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Ming LeiNovartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA).
Allan SaulSclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy).
Roberto AdamoGSK, Via Fiorentina 1, 53100 Siena (Italy).
Calman A MacLennanJenner Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ (UK).
Francesca MicoliSclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy). francesca.x.micoli@gsk.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of glycoconjugates with defined connectivity were synthesized to investigate the impact of coupling Salmonella typhimurium O-antigen to different amino acids of CRM197 protein carrier. In particular, two novel methods for site-selective glycan conjugation were developed to obtain conjugates with single attachment site on the protein, based on chemical modification of a disulfide bond and pH-controlled transglutaminase-catalyzed modification of lysine, respectively. Importantly, conjugation at the C186-201 bond resulted in significantly higher anti O-antigen bactericidal antibody titers than coupling to K37/39, and in comparable titers to conjugates bearing a larger number of saccharides. This study demonstrates that the conjugation site plays a role in determining the immunogenicity in mice and one single attachment point may be sufficient to induce high levels of bactericidal antibodies.

Indexed as

AnimalsFemaleGlycoconjugatesMiceMice, Inbred C57BLModels, MolecularMolecular ConformationO AntigensSalmonella typhimuriumSalmonella VaccinesGlycoconjugatesO AntigensSalmonella Vaccinescarbohydratesglycoproteinsprotein modificationsolmonellavaccines

Identifiers

PMID26350581
PMCPMC4648054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.